Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | PALB2 |
| Variant | Y1183* |
| Impact List | nonsense |
| Protein Effect | loss of function |
| Gene Variant Descriptions | PALB2 Y1183* results in a premature truncation of the Palb2 protein at amino acid 1183 of 1186 (UniProt.org). Y1183* confers a loss of function to the Palb2 protein as demonstrated by decreased protein stability (PMID: 31757951), and impaired homology-directed DNA repair activity compared to wild-type in cultured cells lacking Tp53 (PMID: 31636395, PMID: 31757951). |
| Associated Drug Resistance | |
| Category Variants Paths |
PALB2 mutant PALB2 inact mut PALB2 Y1183* |
| Transcript | NM_024675.4 |
| gDNA | chr16:g.23603471G>T |
| cDNA | c.3549C>A |
| Protein | p.Y1183* |
| Source Database | RefSeq |
| Genome Build | GRCh38/hg38 |
| Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
|---|---|---|---|---|---|
| NM_024675.4 | chr16:g.23603471G>T | c.3549C>A | p.Y1183* | RefSeq | GRCh38/hg38 |
| NM_024675.3 | chr16:g.23603471G>T | c.3549C>A | p.Y1183* | RefSeq | GRCh38/hg38 |
| NM_024675 | chr16:g.23603471G>T | c.3549C>A | p.Y1183* | RefSeq | GRCh38/hg38 |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| PALB2 Y1183* | Advanced Solid Tumor | sensitive | Olaparib | Preclinical - Cell culture | Actionable | In a preclinical study, treatment with Lynparza (olaparib) resulted in decreased survival of TP53-knockout cells expressing PALB2 Y1183* in culture (PMID: 31757951). | 31757951 |
| PALB2 Y1183* | Advanced Solid Tumor | sensitive | Cisplatin | Preclinical - Cell culture | Actionable | In a preclinical study, Platinol (cisplatin) treatment decreased viability of cells expressing PALB2 Y1183* in culture (PMID: 31757951). | 31757951 |